16th Jun 2026 07:00
4basebio Plc - Notice of Investor Presentation4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio PLC
("4basebio" or the "Company")
Notice of Investor Presentation
CAMBRIDGE, UK – 16 June 2026 – 4basebio PLC (AIM: 4BB),a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it will provide a live investor presentation on 29 June 2026.
Dr. Amy Walker, Chief Executive Officer, and Christine Wolosin, Chief Commercial Officer, will provide a live presentation via the Investor Meet Company platform on 29 June 2026 at 17:00 BST. No new material information will be disclosed during the event.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 28 Jun 2026, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet 4basebio PLC via:
https://www.investormeetcompany.com/4basebio-plc/register-investor
Investors who already follow 4basebio PLC on the Investor Meet Company platform will automatically be invited.
For further enquiries, please contact:
| 4basebio PLC |
| Dr. Amy Walker, CEO |
| +44 (0)12 2396 7943
|
| Cairn Financial Advisers LLP (Nominated Adviser) |
| Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880 |
| Cavendish Capital Markets Limited (Joint Broker) |
| Geoff Nash / Nigel Birks +44 (0)20 7220 0500 |
| RBC Capital Markets (Joint Broker) |
| Kathryn Deegan / Matthew Coakes +44 (0)20 7653 4000 |
| ICR Healthcare (Media and Investor Relations) |
| Mary-Jane Elliott / Jessica Hodgson +44 (0)203 707 5700 |
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.
For more information, visit 4basebio.com .
Related Shares:
4basebio Plc